European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.3. Long-term immunosuppression. Toxicity of immunosuppression.
A. Careful long-term monitoring of graft recipients is mandatory to discover signs of immunosuppressive drug toxicity, in particular nephrotoxicity. B. In the case of a discrepancy between the drug dose and signs of toxicity, then a thorough pharmacokinetic analysis should be performed. C. Cardiovascular, renal and metabolic risks and the risk of de novo malignancy must be considered in a long-term monitoring programme.